Open AccessEffectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience
Author(s) -
Gerardo Calderón,
Daniel Gonzalez-Izundegui,
Kuangda L Shan,
Oscar A Garcia-Valencia,
Lizeth Cifuentes,
Alejandro Campos,
Maria L. CollazoClavell,
Meera Shah,
Daniel L. Hurley,
Haitham S. Abu Lebdeh,
Mayank Sharma,
Kristine Schmitz,
Matthew M. Clark,
Karen Grothe,
Manpreet S. Mundi,
Michael Camilleri,
Barham K. Abu Dayyeh,
Maria Daniela Hurtado Andrade,
Mohamad Mokadem,
Andrés Acosta
Publication year - 2021
Publication title -
international journal of obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.663
H-Index - 225
eISSN - 1476-5497
pISSN - 0307-0565
DOI - 10.1038/s41366-021-01019-6
Subject(s) - medicine , phentermine , weight loss , topiramate , weight management , adverse effect , liraglutide , clinical trial , cohort , dosing , randomized controlled trial , obesity , pediatrics , type 2 diabetes , diabetes mellitus , epilepsy , psychiatry , endocrinology
Randomized clinical trials have proven the efficacy and safety of Food and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use. It is unclear whether these outcomes can be replicated in real-world clinical practice where clinical complexities arise. The aim of this study was to evaluate the effectiveness and side effects of these medications in real-world multidisciplinary clinical practice settings.